Literature DB >> 28126361

Antigen-specific secretion of IFNγ and CXCL10 in whole blood assay detects Mycobacterium leprae infection but does not discriminate asymptomatic infection from symptomatic leprosy.

Emerith Mayra Hungria1, Aline Araújo Freitas1, Maria Araci Andrade Pontes2, Heitor Sá Gonçalves2, Ana Lúcia Osório Maroccolo Sousa1, Maurício Barcelos Costa1, Mirian Lane Oliveira Rodrigues Castilho3, Malcolm S Duthie4, Mariane Martins Araújo Stefani5.   

Abstract

To advance toward a whole blood assay (WBA)-based test capable of facilitating the diagnosis of paucibacillary (PB) leprosy, we evaluated a prototype in-tube WBA using combinations of Mycobacterium leprae antigens. Blood was collected from newly diagnosed untreated PB (n=38), multibacillary (MB) (n=30), healthy household contacts (HHC) of MB (n=27), and endemic controls (n=61) residing in Goiânia and Fortaleza, Brazil. Blood was incubated with M. leprae cell sonicate, recombinant proteins (46f+LID-1; ML0276+LID-1), or controls (phosphate-buffered saline, phytohemagglutinin, M. tuberculosis purified protein derivative). Antigen-specific IFNγ production was observed in 71-84% and 55% of PB and HHC, respectively. Antigen-specific CXCL10 levels were similarly assessed to determine if, unlike IFNγ, CXCL10 could differentiate PB from HHC with repeated exposure/asymptomatic M. leprae infection. The CXCL10 levels induced in response to M. leprae antigens could not, however, differentiate PB from HHC. Despite these limitations, the WBAs reported here still represent important tools for assessing M. leprae infection rates and evaluating the impact of control measures.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CXCL10; Cell-mediated immunity; Diagnosis; IFNγ; Leprosy; Whole blood assay

Mesh:

Substances:

Year:  2017        PMID: 28126361     DOI: 10.1016/j.diagmicrobio.2017.01.002

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  4 in total

Review 1.  Drug Delivery Systems on Leprosy Therapy: Moving Towards Eradication?

Authors:  Luíse L Chaves; Yuri Patriota; José L Soares-Sobrinho; Alexandre C C Vieira; Sofia A Costa Lima; Salette Reis
Journal:  Pharmaceutics       Date:  2020-12-11       Impact factor: 6.321

2.  Transcriptomic Analysis of Mycobacterium leprae-Stimulated Response in Peripheral Blood Mononuclear Cells Reveal Potential Biomarkers for Early Diagnosis of Leprosy.

Authors:  You-Hua Yuan; Jian Liu; Yuan-Gang You; Xiao-Hua Chen; Lian-Chao Yuan; Yan Wen; Huan Ying Li; Ying Zhang
Journal:  Front Cell Infect Microbiol       Date:  2021-12-21       Impact factor: 5.293

3.  Utility of Multi-target Nested PCR and ELISPOT Assays for the Detection of Paucibacillary Leprosy: A Possible Conclusion of Clinical Laboratory Misdiagnosis.

Authors:  Haiqin Jiang; Ying Shi; Santosh Chokkakula; Wenyue Zhang; Siyu Long; Zhenzhen Wang; Wenming Kong; Heng Long; Limei Wu; Lihua Hu; Qiang Yao; Hongsheng Wang
Journal:  Front Cell Infect Microbiol       Date:  2022-04-11       Impact factor: 6.073

4.  Evaluation of antigen-specific immune responses for leprosy diagnosis in a hyperendemic area in China.

Authors:  Xiaohua Chen; Yuan-Gang You; You-Hua Yuan; Lian Chao Yuan; Ying Zhang; Wen Yan
Journal:  PLoS Negl Trop Dis       Date:  2018-09-24
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.